Literature DB >> 2839728

The potential pathophysiological role of platelet-activating factor in human diseases.

C Kroegel1.   

Abstract

Platelet-activating factor (PAF) is a new phospholipid mediator released from various cell types and tissues by the catalytic action of phospolipase A2 and acetyl transferase upon immunological and non-immunological stimuli. It activates the cells by binding to specific binding sites. PAF exhibits a broad range of biological and pharmacological activities including platelet and neutrophil aggregation, eosinophil chemotaxis, bronchoconstriction, hypotension, and acute renal failure. In addition, PAF is involved in acute graft rejection, endotoxin shock, and gastrointestinal ulceration. Furthermore, it closely mimics the pathology of bronchial asthma and is cabable of producing most of the phenomena seen in inflammation. So far several PAF antagonists have been described and shown to afford protection. In future, pharmacological studies using such antagonists will help to elucidate the pathophysiological role of PAF in human diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839728     DOI: 10.1007/BF01737939

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  30 in total

1.  Structural analysis of purified platelet-activating factor by lipases.

Authors:  J Benveniste; J P Le Couedic; J Polonsky; M Tence
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

2.  Intravascular aggregation and pulmonary sequestration of platelets during IgE-induced systemic anaphylaxis in the rabbit: abrogation of lethal anaphylactic shock by platelet depletion.

Authors:  R N Pinckard; M Halonen; J D Palmer; C Butler; J O Shaw; P M Henson
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

Review 3.  Perspectives in platelet-activating factor research.

Authors:  P Braquet; L Touqui; T Y Shen; B B Vargaftig
Journal:  Pharmacol Rev       Date:  1987-06       Impact factor: 25.468

4.  Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021.

Authors:  P Braquet; A Etienne; C Touvay; R H Bourgain; J Lefort; B B Vargaftig
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

5.  Is platelet activating factor (PAF) a mediator of endotoxin shock?

Authors:  Z Terashita; Y Imura; K Nishikawa; S Sumida
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

6.  The role of circulating cells in skin reactions.

Authors:  J Morley; S Sanjar; C P Page; U Bretz
Journal:  Br J Dermatol       Date:  1985-07       Impact factor: 9.302

7.  Pharmacological and neurochemical properties of 1,4-diazepines with two annelated heterocycles ('hetrazepines').

Authors:  K H Weber; F J Kuhn; K Böke-Kuhn; E Lehr; P B Danneberg; D Hommer; S M Paul; P Skolnick
Journal:  Eur J Pharmacol       Date:  1985-02-12       Impact factor: 4.432

8.  Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.

Authors:  T W Doebber; M S Wu; J C Robbins; B M Choy; M N Chang; T Y Shen
Journal:  Biochem Biophys Res Commun       Date:  1985-03-29       Impact factor: 3.575

Review 9.  Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets.

Authors:  S Ito; G Camussi; C Tetta; F Milgrom; G Andres
Journal:  Lab Invest       Date:  1984-08       Impact factor: 5.662

10.  Potent ulcerogenic actions of platelet-activating factor on the stomach.

Authors:  A C Rosam; J L Wallace; B J Whittle
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

View more
  3 in total

1.  Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia.

Authors:  G Giers; H Janzarik; E R Kempe; C Mueller-Eckhardt
Journal:  Blut       Date:  1990-07

Review 2.  The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging.

Authors:  C Kroegel; C Kortsik; N Kroegel; H Matthys
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

3.  Platelet-Activating Factor-Induced Reduction in Contact Hypersensitivity Responses Is Mediated by Mast Cells via Cyclooxygenase-2-Dependent Mechanisms.

Authors:  Jesus A Ocana; Eric Romer; Ravi Sahu; Sven-Christian Pawelzik; Garret A FitzGerald; Mark H Kaplan; Jeffrey B Travers
Journal:  J Immunol       Date:  2018-04-25       Impact factor: 5.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.